Financing Drugs in South-East Asia - Report of the First Meeting of the WHO/SEARO Working Group on Drug Financing, Korat, Thailand, 26-28 November 1996 - Health Economics and Drugs Series No. 004
(1997; 72 pages) View the PDF document
Table of Contents
Open this folder and view contentsExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Country presentations on drug financing
Open this folder and view contents3. Korat provincial field visit
Open this folder and view contents4. Drug financing issues
Open this folder and view contents5. Country priorities for drug financing
Open this folder and view contents6. Priorities for work group action
Close this folder7. Conclusions and recommendations
View the document7.1 Country priorities for action
View the document7.2 Recommendations
View the documentAnnex A. Agenda
View the documentAnnex B. List of participants
View the documentAnnex C. List of documents
View the documentAnnex D. Message from Regional Director, WHO South-East Asia Region
Open this folder and view contentsAnnex E. Evaluation of the meeting. Priorities for the Working Group
 

7.2 Recommendations

The Working Group members agreed on the following recommendations:

1. Member Countries should strengthen national and local drug financing schemes to ensure equity and access (availability and affordability) to essential drugs.

2. The Ministry of Health, in collaboration with the Ministry of Finance (Treasury, other relevant ministries), has the obligation to ensure adequate financing for essential drugs to meet the basic needs of the population.

3. If cost-sharing is introduced, revenues should be used to supplement government allocations for health and drug financing, and not as a substitute for government financing of health and essential drugs.

4. Financial and other economic mechanisms to promote rational use of drugs should be identified.

5. The Ministry of Health should explore ways to achieve optimal public and private financing of health and drugs, in order to achieve equity of access and quality of care.

6. If cost-sharing is introduced, policy and guidelines should be formulated by the Ministry of Health to define the objectives, responsibilities, and method of operation for the cost-sharing scheme.

7. Appropriate pricing policies should be formulated by the government to ensure that prices of drugs, especially essential drugs, are affordable for the majority of the population.

Next Meeting: Yogyakarta, Indonesia in November 1997.

 

to previous section to next section
 

Last updated: May 3, 2013